JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hannon, J. P.
Right arrow Articles by Fozard, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hannon, J. P.
Right arrow Articles by Fozard, J. R.

Vol. 302, Issue 2, 725-730, August 2002

Suppression of Adenosine A3 Receptor-Mediated Hypotension and Mast Cell Degranulation in the Rat by Dexamethasone

Jason P. Hannon, Bruno Tigani, Henk-Jan Schuurman and John R. Fozard

Research Department, Novartis Pharma AG, Basel, Switzerland

Dexamethasone increases the expression of adenosine A3 receptors and augments degranulation in response to their activation in the rat basophilic leukemia cell line, RBL-2H3. We have studied the effects of dexamethasone on mast cell activation induced by A3 receptor stimulation in vivo. Administration of the A3 receptor agonist APNEA [N6-2-(4 aminophenyl)ethyladenosine; 10-30 µg kg-1 i.v.] to anesthetized Sprague-Dawley rats induced falls in blood pressure. Pretreatment with dexamethasone (1 mg kg-1, i.p., -24 h) blocked the hypotensive response to APNEA but not those induced by the A1 receptor agonist N6-cyclopentyladenosine, the A2A receptor agonist 2-[p-(2-carboxyethyl)phenylamino]-5'-N-ethylcarboxamidoadenosine, or the mast cell degranulating agent compound 48/80 (100-300 µg kg-1, i.v.). APNEA (10 and 30 µg kg-1, i.v.) and compound 48/80 (100 and 300 µg kg-1, i.v.) increased plasma histamine concentrations dose dependently. Pretreatment with dexamethasone significantly inhibited the increases induced by the lower doses of each compound. APNEA induced degranulation of mast cells in thymus but not in skin or skeletal muscle, whereas compound 48/80 induced degranulation in each tissue. Pretreatment with dexamethasone inhibited APNEA-induced degranulation of mast cells in the thymus and slightly, yet significantly, reduced degranulation induced by compound 48/80. Thus, in contrast to the findings in RBL-2H3 cells in vitro, in the whole animal, dexamethasone down-regulates the response of the mast cell to A3 receptor activation. The qualitatively similar effects on compound 48/80 suggest that dexamethasone suppresses mast cell responsiveness by modulating site(s) downstream from the adenosine A3 receptor, possibly at the level of the Gi family of trimeric GTP-binding proteins.


0022-3565/02/3022-0725$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.